WO2015086239A1 - Composition de thymoquinone pour le traitement de maladies neurodégénératives - Google Patents

Composition de thymoquinone pour le traitement de maladies neurodégénératives Download PDF

Info

Publication number
WO2015086239A1
WO2015086239A1 PCT/EP2014/074250 EP2014074250W WO2015086239A1 WO 2015086239 A1 WO2015086239 A1 WO 2015086239A1 EP 2014074250 W EP2014074250 W EP 2014074250W WO 2015086239 A1 WO2015086239 A1 WO 2015086239A1
Authority
WO
WIPO (PCT)
Prior art keywords
thymoquinone
composition
neurodegenerative diseases
extract
indirubin
Prior art date
Application number
PCT/EP2014/074250
Other languages
English (en)
Inventor
Axel Brattstroem
Original Assignee
Brattström-Junghanns Gbr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brattström-Junghanns Gbr filed Critical Brattström-Junghanns Gbr
Publication of WO2015086239A1 publication Critical patent/WO2015086239A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A61K36/315—Isatis, e.g. Dyer's woad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal

Definitions

  • the present invention is directed to thymoquinone or thymoquinone-comprising compositions for use in the treatment of neurodegenerative diseases such as Parkinson, Huntington and Alzheimer ' s disease.
  • AD Alzheimer ' s disease
  • Plants have been investigated for controlling the severity and progression of AD. Siderits scardica, melissa, rosemary, sage and ginkgo are presently being investigated experimentally in vitro or in vivo and in some cases even clinically.
  • Thymoquinone is the main active constituent of the oil of Nigella sativa (NS) (also called black seed, cumin, black onion seed, nutmeg flower, black caraway, Roman coriander and fennel flower).
  • Nigella sativa oil contains an abundance of conjugated linoleic acid, thymoquinone, nigellone (dithymoquinone), melanthin, nigilline, damasce- nine and tannins.
  • Melanthin is toxic in large doses and nigelline is paralytic.
  • TQ is an antioxidant that supposedly protects from heart, liver and kidney damage, it has analgesic, anti-convulsant, anti-angiogenic and anti-epileptic effects.
  • TQ induces relaxation in isolated rat pulmonary arteries that had been pre-contracted by phenylephrine, probably in part by activation of ATP- sensitive potassium channels and possibly by non-competitive blocking of serotonin, alphal and endothelin receptors (G.M. Suddek, J. Ethnopharmacol.
  • TQ reduces lipid peroxidation upon intraperitoneal injection immediately after global ischemia-reperfusion injury in the rat hippocampus in a rat reperfusion model (Hossei- nzadeh et al., Phytomedicine 14:621 -627, 2007); and TQ improves aging-related endothelial dysfunction in the rat mesentery artery, at least in part, through inhibition of oxidative stress and normalization of the angiotensin system (Idris-Khodja and Schini- Kerth, Naunyn Schmiedebergs Arch. Pharmacol, 385(7):749-58, 2012).
  • TQ has also shown a promising neuroprotective effect on the spatial cognitive functions of rats suffering from global cerebrovascular hypofusion (Azzubaidi et al., Acta Neurobiol. Exp., 72:154-1665, 2012).
  • TQ has also been associated with AD.
  • TQ protected cultured rat primary neurons against amyloid ⁇ -induced neurotoxicity, probably because of its antioxidant and antiinflammatory effects and was suggested as a possible promising candidate for AD treatment (Alhebshi and Gotoh, Biochem. Biophys. Res. Comm., 433(4):362-7, 2013).
  • TQ improved memory, attention and cognition.
  • Nigella sativa seed could be considered as a potential food supplement for preventing or slowing progression of AD was considered to need further investigations, and a study with AD patients with a large population size for a longer period of time was recommended before using Nigella sativa daily, and extensive phytochemical investigations were recommended for novel drug discovery use of Nigella sativa for treating cognitive disorders (Shahdaat et al., Journal of Ethnopharmacology, 148:780-786, 2013).
  • the alkaloid indirubin is the main active agent in Indigo naturalis, a dark blue powder prepared from the leaves of dye plants including Baphicacanthus cusia (Acanthaceae), Polygonum tinctorium (Polygonaceae), Isatis indigotica (Brassicaceae) and Indigofera suffrutticosa (Fabacea) and Isatis tinctoria.
  • the blue powder of Indigo naturalis is typically produced by crushing, fermenting and adding calcium to the plant.
  • Indigo naturalis demonstrated efficacy in a clinical study with 42 psoriasis patients, which were treated for twelve weeks with an ointment containing indigo, resulting in symptom improvements in 81 % of the patients (Reuter et al., JDDG, 10, 2010, vol. 8, p. 788-793).
  • Indirubin-comprising extracts from Isatis tinctoria have proven effective for treating allergen-induced airway inflammation (Brattstrom et al., Phytomedicine, 17:551 - 556, 2010).
  • Indirubin has anti-tumoral effects that appear to correlate with its antimitotic effects and it is a potent inhibitor of cyclin-dependent cyclases (CDKs).
  • the objective is solved by the provision of thymoquinone or thymoquinone- comprising compositions for use in the treatment of neurodegenerative diseases.
  • an extract from the seeds of Nigella sativa (NS) or the active constituent thymoquinone (TQ) can be prepared for use in the treatment of neurodegenerative diseases.
  • neurodegenerative diseases as used herein, is defined as the umbrella term for the progressive loss of structure and/or function of neurons. Neurodegenerative diseases are incurable and result in progressive degeneration and/or death of neurons. This causes problems with mental functioning (called dementia).
  • the neurodegenerative diseases for treatment according to the invention are preferably selected from the group consisting of Parkinson, Huntington and Alzheimer ' s disease.
  • thymoquinone as used herein is meant to refer to the chemical substance 2-isopropyl-5-methylbenzo-1 ,4-quinone and encompasses all chemical and metabolic derivatives thereof that essentially retain the physiological activity of basic thymoquinone, e.g. nigellone (dithymoquinone).
  • Thymoquinone is a chemically rather simple methyl- benzo-1 ,4-quinone derivative and can be produced synthetically or it can be isolated from or enriched in the volatile oil or seed extract of Nigella sativa. It is preferred that the thymoquinone-comprising composition for use in the present invention comprises extract or oil, preferably volatile oil from Nigella sativa seed.
  • a Nigella sativa seed extract can be produced as hydrodestillation, steam distillation solvent extraction, supercritical fluid extraction, microwave assisted extraction or solid phase microextraction (Liu et al., Mini- Reviews in Medicinal Chemistry, 1 1 :947-955, 201 1 ).
  • the extract for use in the present invention is a cold-pressurized volatile oil.
  • the extract solvent for producing the extract of the present invention is supercritical carbon dioxide, preferably together with at least one organic, more preferably hydrophilic, most preferably alcoholic co-solvent.
  • Nigella sativa oil comprises a number of constituents that are susceptible to oxidation, e.g. unsaturated fatty acids such as linoleic acid (Edris AE, J. Dietary Suppl., 8:34- 42, 2011 ).
  • unsaturated fatty acids such as linoleic acid (Edris AE, J. Dietary Suppl., 8:34- 42, 2011 ).
  • the thymoquinone-comprising composition for use in the invention additionally comprises an antioxidant, preferably selected from the group consisting of balm (melissa), rosemary and sage, preferably rosmarinus officinalis and salvia officinalis (sage) extract, which are high in rosmarinic acid content.
  • an antioxidant preferably selected from the group consisting of balm (melissa), rosemary and sage, preferably rosmarinus officinalis and salvia officinalis (sage) extract, which are high in rosmarinic acid content.
  • the thymoquinone-comprising composition for use in the present invention additionally comprises indirubin, preferably in the form of an isatis tinctoria extract.
  • indirubin is meant to refer to the chemical substance as such, i.e. 3-(1 ,3-dihydro-3-oxo-2H-indol-2-yliden)-1 ,3-dihydro-2H-indol-2-on, and encompasses all chemical and metabolic derivatives thereof that essentially retain the physiological activity of basic indirubin, e.g. indirubin-3 ' -oxime.
  • Indirubin is a chemically rather simple indol derivative and can be produced synthetically or it can be isolated from or enriched in an extract from various plants (see above). It is preferred that the thymoquinone-comprising composition for use in the present invention comprises indirubin from an Isatis tinctoria exctract.
  • an indirubin-containing extract can be produced as a lipophylic extract (Recio et al., Planta Med, 72:539-546, 2006; Mohn et al., Planta Med, 73:151 -156, 2007).
  • the extract solvent for producing the indirubin extract of the present invention is supercritical carbon dioxide, preferably together with at least one organic, more preferably hydrophilic, most preferably alcoholic co-solvent.
  • both thymoquinone and indirubin are present in the composition in physiologically effective amounts each.
  • the ratio of thymoquinone and indirubin (TQ:IR) in the composition for use in the present invention is at least about 1 :1 - 10:1 , preferably 4:1 - 6:1 , most preferably 5:3 - 7:3 or about 6:4.
  • TQ:IR ratios are 1 :1 , 1 :2, 1 :3, 1 :4, 1 :5, 1 :6, 1 :7, 1 :8, 1 :9, 1 :10, 2:1 , 3:1 , 4:1 , 5:1 , 6:1 , 7:1 , 8:1 , 9:1 , 10:1 (TQ:IR).
  • the thymoquinone, the thymoquinone-comprising composition and preferably the thymoquinone and indirubin-comprising compositions for use in the present invention have utility for the prophylactic and/or therapeutic treatment of neurodegenerative diseases.
  • treatment and prophylaxis of neurodegenerative diseases relates to the treatment of an existing neurodegenerative disease for alleviating, reducing or getting rid of the disease or at least one or more of its symptoms as well as the treatment of future neurodegenerative diseases for preventing their occurrence, recurrence or the occurrence or recurrence of symptoms thereof.
  • the present invention relates to the use of thymoquinone, a thymoquinone-comprising composition and preferably a thymoquinone and indirubin-comprising composition as described above for the preparation of a medicament for the prophylactic and/or therapeutic treatment of neurodegenerative diseases, preferably selected from the group consisting of Parkinson, Huntington and Alzheimer ' s disease.
  • a further aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising thymoquinone, preferably thymoquinone together with an antioxidant, preferably an antioxidant selected from the group consisting of balm, rosemary and sage, preferably balm extract, rosmarinus officinalis and salvia officinalis (sage) extract, which are high in rosmarinic acid content.
  • an antioxidant preferably an antioxidant selected from the group consisting of balm, rosemary and sage, preferably balm extract, rosmarinus officinalis and salvia officinalis (sage) extract, which are high in rosmarinic acid content.
  • thymoquinone and indirubin most preferably, wherein at least one, preferably all of thymoquinone, indirubin and/or the antioxidants) are present as a plant extract.
  • the present invention pertains to a method for the prophylactic and therapeutic treatment of neurodegenerative diseases, preferably selected from the group consisting of Parkinson, Huntington and Alzheimer ' s disease, comprising the step of administering a composition of the invention in a physiologically effective amount to a patient in need thereof.
  • neurodegenerative diseases preferably selected from the group consisting of Parkinson, Huntington and Alzheimer ' s disease
  • compositions for use in the invention may be administered enteral, parenteral, local, e.g. topical including a transdermal patch, in any conventional dosage form in any conventional manner.
  • the preferred mode of administration is preferably in a solid or liquid dosage form.
  • compositions may be administered alone or in combination with adjuvants that enhance stability of the active components, facilitate administration of pharmaceutical compositions containing them, provide increased dissolution or dispersion, support bioavailability, provide adjunct therapy, and the like, including other active ingredients.
  • adjuvants that enhance stability of the active components, facilitate administration of pharmaceutical compositions containing them, provide increased dissolution or dispersion, support bioavailability, provide adjunct therapy, and the like, including other active ingredients.
  • combination therapies utilize lower dosages of the conventional therapeutics, thus avoiding possible toxicity and adverse side effects incurred when those agents are used as monotherapies.
  • dosage forms of the compounds and extracts described herein include pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the art. These carriers and adjuvants include, for example, ion exchangers, alumina, aluminium stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes and cellulose-based substances. Also, maltodextrin can be used to produce a free-flowing dry extract which is particularly suitable for further processing.
  • Preferred dosage forms include solid, liquid, solution, suspension, emulsion, reconstitutable powder and transdermal patch. Controlled release dosage forms with or without immediate release portions are also envisaged. Methods for preparing such dosage forms are known (see, for example, H. C. Ansel and N.
  • Dosage levels and requirements are well-recognized in the art and may be selected by those of ordinary skill in the art from available methods and techniques suitable for a particular patient. Although one dose per day may be sufficient, up to 5 doses per day may be administered. As the person skilled in the art will appreciate, lower or higher doses may be required depending on particular factors. For instance, specific doses and treatment regimens will depend on factors such as the patient's general health profile, the severity and course of the patient's disorder or disposition thereto, and the judgment of the treating physician which includes interaction potentials with other needed medication.
  • the extracts of the present invention can be administered the same way as other chemical drugs or plant extracts and pharmaceutical compositions thereof.

Abstract

La présente invention concerne la thymoquinone ou des compositions comprenant de la thymoquinone pour leur utilisation dans le traitement de maladies neurodégénératives telles que la maladie d'Alzheimer (MA).
PCT/EP2014/074250 2013-12-09 2014-11-11 Composition de thymoquinone pour le traitement de maladies neurodégénératives WO2015086239A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13196175 2013-12-09
EP13196175.7 2013-12-09

Publications (1)

Publication Number Publication Date
WO2015086239A1 true WO2015086239A1 (fr) 2015-06-18

Family

ID=49726605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/074250 WO2015086239A1 (fr) 2013-12-09 2014-11-11 Composition de thymoquinone pour le traitement de maladies neurodégénératives

Country Status (1)

Country Link
WO (1) WO2015086239A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105616392A (zh) * 2016-03-29 2016-06-01 复旦大学附属金山医院 百里醌在制备防治癫痫持续状态脑损伤的药物中的应用
WO2019055550A2 (fr) 2017-09-12 2019-03-21 Jina Pharmaceuticals, Inc. Procédés de préparation de compositions contenant de la thymoquinone
US10485837B2 (en) 2016-11-07 2019-11-26 Akay Flavours & Aromatics Pvt, Ltd Composition of nigella sativaseeds to treat anxiety, stress and sleep disorders with significant memory enhancement properties and a process for producing the same
US10842738B1 (en) * 2019-09-09 2020-11-24 Max C. Champie Nasal spray using C60 and curcumin
US11179350B2 (en) 2018-12-14 2021-11-23 Max Champie Nutraceutical compositions comprising C60 and Cox-2 inhibitor
WO2022043407A1 (fr) 2020-08-25 2022-03-03 Laouarem Yousra Compositions destinées au traitement des troubles neurologiques

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
ALHEBSHI A H ET AL: "Thymoquinone protects cultured rat primary neurons against amyloid [beta]-induced neurotoxi", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 433, no. 4, 26 March 2013 (2013-03-26), pages 362 - 367, XP028582715, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2012.11.139 *
ALHEBSHI; GOTOH, BIOCHEM. BIOPHYS. RES. COMM., vol. 433, no. 4, 2013, pages 362 - 7
ANDLEEB KHAN ET AL: "Attenuation of AÎ-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress", MOLECULAR AND CELLULAR BIOCHEMISTRY, KLUWER ACADEMIC PUBLISHERS, BO, vol. 369, no. 1 - 2, 1 July 2012 (2012-07-01), pages 55 - 65, XP035104185, ISSN: 1573-4919, DOI: 10.1007/S11010-012-1368-X *
AZZUBAIDI ET AL., ACTA NEUROBIOL. EXP., vol. 72, 2012, pages 154 - 1665
AZZUBAIDI MARWAN SAAD ET AL: "Protective effect of treatment with black cumin oil on spatial cognitive functions of rats that suffered global cerebrovascular hypoperfusion", ACTA NEUROBIOLOGIAE EXPERIMENTALIS (WARSAW), vol. 72, no. 2, 2012, pages 154 - 165, XP055161924 *
BIN SAYEED MUHAMMAD SHAHDAAT ET AL: "The effect ofNigella sativaLinn. seed on memory, attention and cognition in healthy human volunteers", JOURNAL OF ETHNOPHARMACOLOGY, vol. 148, no. 3, 21 May 2013 (2013-05-21), pages 780 - 786, XP028672896, ISSN: 0378-8741, DOI: 10.1016/J.JEP.2013.05.004 *
BRATTSTROM ET AL., PHYTOMEDICINE, vol. 17, 2010, pages 551 - 556
EDRIS AE, J. DIETARY SUPPL., vol. 8, 2011, pages 34 - 42
EWERS ET AL., EXP. GERONTOL., vol. 45, no. 1, 2010, pages 75
G.M. SUDDEK, J. ETHNOPHARMACOL., vol. 127, no. 2, 2010, pages 210 - 4
H. C. ANSEL; N. G. POPOVISH: "Forms and Drug Delivery Systems", 1990, LEA AND FEBIGER, article "Pharmaceutical Dosage"
HOSSEI-NZADEH ET AL., PHYTOMEDICINE, vol. 14, 2007, pages 621 - 627
IDRIS-KHODJA; SCHINI-KERTH; NAUNYN SCHMIEDEBERGS, ARCH. PHARMACOL, vol. 385, no. 7, 2012, pages 749 - 58
JUNG ET AL., NEUROSCIENCE LETTERS, vol. 487, 2011, pages 139 - 143
KHALED RADAD ET AL: "Thymoquinone protects dopaminergic neurons against MPP + and rotenone", PHYTOTHERAPY RESEARCH, vol. 23, no. 5, 1 May 2009 (2009-05-01), pages 696 - 700, XP055161790, ISSN: 0951-418X, DOI: 10.1002/ptr.2708 *
KIM SUNG-JUN ET AL: "CARNOSOL, A COMPONENT OF ROSEMARY (ROSMARINUS OFFICINALIS L.) PROTECTS NIGRAL DOPAMINERGIC NEURONAL CELLS", NEUROREPORT : AN INTERNATIONAL JOURNAL FOR THE RAPID COMMUNICATION OF RESEARCH IN NEUROSCIENCE, LIPPINCOTT WILLIAMS & WILKINS, UK, vol. 17, no. 16, 6 November 2006 (2006-11-06), pages 1729 - 1733, XP009082431, ISSN: 0959-4965, DOI: 10.1097/01.WNR.0000239951.14954.10 *
KULDEEP S SANDHU ET AL: "EVALUATION OF ANTI PARKINSON'S ACTIVITY OF NIGELLA SATIVA (KALONJI) SEEDS IN CHLORPROMAZINE INDUCED EXPERIMENTAL ANIMAL MODEL", INTERNATIONAL JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES2012INTERNATIONAL JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCEIND, vol. 5, no. Suppl.3, 1 January 2013 (2013-01-01), pages 884 - 888, XP055161921, ISSN: 0975-1491 *
LECLERC ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 1, 2001, pages 251 - 260
LECLERC S ET AL: "Indirubins Inhibit Glycogen Synthase Kinase-3b and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 276, no. 1, 5 January 2001 (2001-01-05), pages 251 - 260, XP002188391, ISSN: 0021-9258, DOI: 10.1074/JBC.M002466200 *
LIU ET AL., MINI-REVIEWS IN MEDICINAL CHEMISTRY, vol. 11, 2011, pages 947 - 955
MALIK T ET AL: "Inhibition of haloperidol-induced striatal astrogliosis, parkinsonism and tardive vacuous chewing movements by coadministration of Nigella sativa-oil in rats", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 43, 1 January 2013 (2013-01-01), XP009181944, ISSN: 0190-5295 *
MALIK T ET AL: "Nigella Sativaoil controls astrogliosis, parkinsonism and oral dyskinesia in haloperidol-treated rats", JOURNAL OF NEUROLOGICAL SCIENCES, vol. 333, 15 October 2013 (2013-10-15), XP028721545, ISSN: 0022-510X, DOI: 10.1016/J.JNS.2013.07.377 *
MOHAMMAD BAYAT ET AL: "Neuroprotective properties of Melissa officinalis after hypoxic-ischemic injury both in vitro and in vivo", DARU JOURNAL OF PHARMACEUTICAL SCIENCES, BIOMED CENTRAL LTD, LONDON, UK, vol. 20, no. 1, 3 October 2012 (2012-10-03), pages 42, XP021119783, ISSN: 2008-2231, DOI: 10.1186/2008-2231-20-42 *
MOHN ET AL., PLANTA MED, vol. 73, 2007, pages 151 - 156
NORSHARINA ISMAIL ET AL: "Thymoquinone Prevents [beta]-Amyloid Neurotoxicity in Primary Cultured Cerebellar Granule Neurons", CELLULAR AND MOLECULAR NEUROBIOLOGY, vol. 33, no. 8, 8 October 2013 (2013-10-08), pages 1159 - 1169, XP055161781, ISSN: 0272-4340, DOI: 10.1007/s10571-013-9982-z *
PENGFEI MENG ET AL: "Carnosic acid suppresses the production of amyloid-[beta] 1-42 by inducing the metalloprotease gene TACE/ADAM17 in SH-SY5Y human neuroblastoma cells", NEUROSCIENCE RESEARCH, vol. 75, no. 2, 1 February 2013 (2013-02-01), pages 94 - 102, XP055161845, ISSN: 0168-0102, DOI: 10.1016/j.neures.2012.11.007 *
RECIO ET AL., PLANTA MED, vol. 72, 2006, pages 539 - 546
REUTER ET AL., JDDG, vol. 8, no. 10, 2010, pages 788 - 793
SHAHDAAT ET AL., JOURNAL OF ETHNOPHARMACOLOGY, vol. 148, 2013, pages 780 - 786
SHARAREH DARIANI ET AL: "Thymoquinone Attenuates Astrogliosis, Neurodegeneration, Mossy Fiber Sprouting, and Oxidative Stress in a Model of Temporal Lobe Epilepsy", JOURNAL OF MOLECULAR NEUROSCIENCE, vol. 51, no. 3, 23 November 2013 (2013-11-23), pages 679 - 686, XP055161762, ISSN: 0895-8696, DOI: 10.1007/s12031-013-0043-3 *
YUN DING ET AL: "Indirubin-3'-monoxime rescues spatial memory deficits and attenuates [beta]-amyloid-associated neuropathology in a mouse model of Alzheimer's disease", NEUROBIOLOGY OF DISEASE, vol. 39, no. 2, 1 August 2010 (2010-08-01), pages 156 - 168, XP055161821, ISSN: 0969-9961, DOI: 10.1016/j.nbd.2010.03.022 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105616392A (zh) * 2016-03-29 2016-06-01 复旦大学附属金山医院 百里醌在制备防治癫痫持续状态脑损伤的药物中的应用
US10485837B2 (en) 2016-11-07 2019-11-26 Akay Flavours & Aromatics Pvt, Ltd Composition of nigella sativaseeds to treat anxiety, stress and sleep disorders with significant memory enhancement properties and a process for producing the same
US11007243B2 (en) 2016-11-07 2021-05-18 Akay Flavours & Aromatics Pvt, Ltd Enzyme-assisted supercritical extraction of nigella sativa seeds
WO2019055550A2 (fr) 2017-09-12 2019-03-21 Jina Pharmaceuticals, Inc. Procédés de préparation de compositions contenant de la thymoquinone
WO2019055550A3 (fr) * 2017-09-12 2020-04-02 Jina Pharmaceuticals, Inc. Procédés de préparation de compositions contenant de la thymoquinone
EP3681484A4 (fr) * 2017-09-12 2021-07-28 Jina Pharmaceuticals Inc. Procédés de préparation de compositions contenant de la thymoquinone
US11389413B2 (en) 2017-09-12 2022-07-19 Jina Pharmaceuticals, Inc. Methods of preparing compositions containing thymoquinone
US11179350B2 (en) 2018-12-14 2021-11-23 Max Champie Nutraceutical compositions comprising C60 and Cox-2 inhibitor
US10842738B1 (en) * 2019-09-09 2020-11-24 Max C. Champie Nasal spray using C60 and curcumin
WO2022043407A1 (fr) 2020-08-25 2022-03-03 Laouarem Yousra Compositions destinées au traitement des troubles neurologiques

Similar Documents

Publication Publication Date Title
Gupta et al. Neuroprotective potential of ellagic acid: a critical review
Wu et al. Traditional Chinese medicines and Alzheimer’s disease
Buendia et al. Nrf2–ARE pathway: an emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases
Ong et al. Protective effects of ginseng on neurological disorders
WO2015086239A1 (fr) Composition de thymoquinone pour le traitement de maladies neurodégénératives
Wu et al. New insights into the role and mechanisms of ginsenoside Rg1 in the management of Alzheimer’s disease
Liang et al. The genus Uncaria: A review on phytochemical metabolites and biological aspects
Zanforlin et al. The medicinal chemistry of natural and semisynthetic compounds against Parkinson’s and Huntington’s diseases
Canistro et al. The pharmacological basis of the curcumin nutraceutical uses: An update
US10946053B2 (en) Composition containing mixed extract of mulberry and Poria cocos bark for preventing, improving or treating neurodegenerative disorders
Koynova et al. Natural product formulations for the prevention and treatment of Alzheimer's disease: a patent review
Vasileva et al. Beneficial effect of commercial Rhodiola extract in rats with scopolamine-induced memory impairment on active avoidance
Sivaraman et al. Review on current treatment strategy in Alzheimer’s disease and role of herbs in treating neurological disorders
Lye et al. Exploring new avenues for modifying course of progression of Alzheimer's disease: the rise of natural medicine
Nandy et al. Bacopa monnieri: The neuroprotective elixir from the East—Phytochemistry, pharmacology, and biotechnological improvement
RU2559088C2 (ru) Растительные экстраты для лечения нейродегенеративных заболеваний
EP3632454A1 (fr) Composition contenant un extrait d'écorce de poria cocos pour prévenir, améliorer ou traiter des troubles neurodégénératifs
da S Hage-Melim et al. The impact of natural compounds on the treatment of neurodegenerative diseases
Das et al. Potential of Glyco-withanolides from Withania Somnifera (Ashwagandha) as therapeutic agents for the treatment of Alzheimer’s disease
US20040265403A1 (en) Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory
Shahid Nadeem et al. Protective effect of hirsutidin against rotenone-induced parkinsonism via inhibition of caspase-3/interleukins-6 and 1β
Gorain et al. Mechanistic description of natural herbs in the treatment of dementia: a systematic review
Feng et al. The composition, pharmacological effects, related mechanisms and drug delivery of alkaloids from Corydalis yanhusuo
US10485837B2 (en) Composition of nigella sativaseeds to treat anxiety, stress and sleep disorders with significant memory enhancement properties and a process for producing the same
Singh et al. Therapeutic Approach of Phytomedicine for Dementia: A Review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14801968

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14801968

Country of ref document: EP

Kind code of ref document: A1